Latest Breaking News On - Biohaven therapeutics ltd - Page 1 : comparemela.com

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated.

United statesBrian lestiniMike beyerNushmia khokharShiraj senJennifer porcelliBiohaven ltdSam brown incPrnewswire biohaven ltdBiohaven therapeutics ltdExchange commissionRegeneron pharmaceuticals incGenequantum healthcare coSuzhou ltdTrophoblast cell surfaceAntibody drug conjugate

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven s lead investigational drug from its Molecular Degrader of Extracellular.

United statesNew havenJennifer porcelliMike beyerRegeneron pharmaceuticals incMyostatin programExchange commissionPublic health crisis of obesityPrnewswire biohaven ltdBiohaven therapeutics ltdInnovative approach for improving muscle healthBiohaven ltdSam brown incMolecular degraderExtracellular proteinsMuscular atrophy

Biohaven Doses First Patient With Its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 In Advanced Or Metastatic Epithelial Tumors

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiate

United statesNushmia khokharBrian lestiniShiraj senJennifer porcelliMike beyerSam brown incBiohaven therapeutics ltdBiohaven ltdRegeneron pharmaceuticals incExchange commissionPrnewswire biohaven ltdSuzhou ltdGenequantum healthcare coTrophoblast cell surfaceAntibody drug conjugate

Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting

Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses.

United statesJason lernerJennifer porcelliMike beyerPrnewswire biohaven ltdExchange commissionDeterminants of healthAmerican epilepsy society annual meetingBiohaven therapeutics ltdAmerican epilepsy societySam brown incBiohaven ltdEpilepsy societyAnnual meetingMedical directorEpilepsy clinical lead

Biohaven Pharma (BHVN) Reports Q2, Provides Update on Recent Business Developments

Biohaven Pharma (BHVN) Reports Q2, Provides Update on Recent Business Developments
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMike beyerBiohaven igJennifer porcelliDevelopment rd expensesExchange commissionBiohaven ltdEuropean commissionBiohaven therapeutics ltdBiohaven pharmaceutical holding company ltdSam brown incChief executive officerRecent businessNew drug applicationTwo phaseBiohaven pharmaceutical holding company